Shaun Bagai Biography and Net Worth

CEO of RenovoRx

Mr. Bagai has served as our Chief Executive Officer and director since June 2014. Prior to joining us, Mr. Bagai led Global Market Development for HeartFlow, Inc. from 2011 to 2014, which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development to create value resulting in a company investment to form HeartFlow-Japan. During his tenure at HeartFlow, he successfully orchestrated their largest clinical trial to date and contracted HeartFlow’s first global customers. In addition, Mr. Bagai has launched innovative technologies into regional and global marketplaces in both large corporations and growth-phase novel technology companies. He was instrumental in developing the European market for renal denervation for the treatment of hypertension leading to the acquisition of the first renal denervation company — Ardian, Inc. by Medtronic in 2011. Mr. Bagai is a graduate from the University of California, Santa Barbara with a BSc. in Biology/Pre-Med.

What is Shaun Bagai's net worth?: The estimated net worth of Shaun Bagai is at least $582.83 thousand as of December 17th, 2025. Mr. Bagai owns 340,040 shares of RenovoRx stock worth more than $582,829 as of September 18th. This net worth estimate does not reflect any other investments that Mr. Bagai may own. Learn More about Shaun Bagai's net worth.
How do I contact Shaun Bagai?: The corporate mailing address for Mr. Bagai and other RenovoRx executives is 2570 W. EL Camino Real, Ste. 320,, Mountain View, CA, 94040. RenovoRx can also be reached via phone at (408) 800-2649 and via email at [email protected]. Learn More on Shaun Bagai's contact information.
Has Shaun Bagai been buying or selling shares of RenovoRx?: Shaun Bagai has not been actively trading shares of RenovoRx during the last ninety days. Most recently, on Wednesday, December 17th, Shaun Bagai bought 5,000 shares of RenovoRx stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $4,250.00. Following the completion of the transaction, the chief executive officer now directly owns 340,040 shares of the company's stock, valued at $289,034. Learn More on Shaun Bagai's trading history.
Who are RenovoRx's active insiders?: RenovoRx's insider roster includes Ramtin Agah (Insider), Shaun Bagai (CEO), Ron Kocak (Vice President of Finance and Controller), Laurence Marton (Director), and Mark Voll (CFO). Learn More on RenovoRx's active insiders.
Are insiders buying or selling shares of RenovoRx?: In the last year, RenovoRx insiders bought shares 9 times. They purchased a total of 94,000 shares worth more than $79,993.85. The most recent insider tranaction occured on May, 19th when CFO Mark Voll bought 25,000 shares worth more than $19,750.00. Insiders at RenovoRx own 9.4% of the company. Learn More about insider trades at RenovoRx.
Information on this page was last updated on 5/19/2026.

Shaun Bagai Insider Trading History at RenovoRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2025	Buy	5,000	$0.85	$4,250.00	340,040
8/25/2025	Buy	5,000	$0.91	$4,550.00	330,040
8/22/2025	Buy	5,000	$0.95	$4,750.00	325,040
4/15/2025	Buy	7,500	$0.91	$6,825.00	320,040
4/9/2025	Buy	10,000	$0.83	$8,300.00	312,540
4/7/2025	Buy	10,000	$0.83	$8,300.00	302,540
5/19/2022	Buy	5,500	$2.05	$11,275.00	251,557

Shaun Bagai Buying and Selling Activity at RenovoRx

RenovoRx Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Today's Range

Now: $1.70

$1.67

$1.75

50 Day Range

MA: $1.35

$0.85

$2.52

2 Week Range

Now: $1.70

$0.70

$2.59

Volume

388,854 shs

Average Volume

459,926 shs

Market Capitalization

$76.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12